Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary and booster MenACWY-TT vaccination in Dutch elderly
2019-001301-24Phase 4Active
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Feb 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Meningococcal polysaccharide vaccine group W-135 in meningococcal disease (2 cohorts), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Meningococcal serum bactericidal antibody levels over time. Started Feb 2020; status: active.
02
Drugs
Meningococcal polysaccharide vaccine group W-135
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2019-001301-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001301-24.